Evaluation of the Modular Adaptive Radiotherapy System (MARS)

Evaluation of the Modular Adaptive Radiotherapy System (MARS) - MARS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037489

Enrollment

1000

Registered

2025-08-18

Start date

2023-10-25

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who receive radiation therapy at Ethos as part of their oncological therapy

Interventions

Group 1: Target volume definition, radiation dose, and organ protection at risk are performed according to local treatment standards or the study protocol for study patients. In addition to the daily

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patient consent • Patient age = 18 years. • Capacity to consent • Presence of a need for radiotherapy and the presumed benefit of Ethos radiation therapy (e.g., expected change in the target volume during treatment, proximity to radiation-sensitive organs at risk with varying anatomy)

Exclusion criteria

Exclusion criteria: • Patient refusal to participate in the study • Patient unable to consent • Severe claustrophobia • Non-MR-compatible implants (pacemaker, defibrillator, large metal implants, etc.) • Pregnancy

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is to descriptively characterize modular adaptive radiotherapy (MARS). This includes radiotherapy itself (tumor type, single dose, fraction number, session duration), patient satisfaction (MR-Linac Questionnaire), toxicity, and the oncological outcome of the radiation therapy. This also allows a comparison of the modular system with hybrid devices (e.g., MR-Linac).	—

Measure

Time frame

The primary objective of the study is to descriptively characterize modular adaptive radiotherapy (MARS). This includes radiotherapy itself (tumor type, single dose, fraction number, session duration), patient satisfaction (MR-Linac Questionnaire), toxicity, and the oncological outcome of the radiation therapy. This also allows a comparison of the modular system with hybrid devices (e.g., MR-Linac).

—

Secondary

Measure	Time frame
Second, the frequency of modular imaging will be recorded in order to determine the optimal frequency of modular imaging in the future. The current department-specific standard of a weekly MRI examination could thus be prospectively reduced or expanded to specific time points depending on the tumor entity. The third objective concerns centers that have a patient shuttle. By descriptively documenting those radiation therapy sessions in which an MRI in the radiation position was performed immediately beforehand, patient and treatment characteristics can be derived that indicate a particular benefit of the shuttle-based concept.	—

Measure

Time frame

Second, the frequency of modular imaging will be recorded in order to determine the optimal frequency of modular imaging in the future. The current department-specific standard of a weekly MRI examination could thus be prospectively reduced or expanded to specific time points depending on the tumor entity. The third objective concerns centers that have a patient shuttle. By descriptively documenting those radiation therapy sessions in which an MRI in the radiation position was performed immediately beforehand, patient and treatment characteristics can be derived that indicate a particular benefit of the shuttle-based concept.

—

Countries

Germany

Contacts

Public ContactFabian Weykamp

Universität Heidelberg, Klinik für Radioonkologie und Strahlentherapie

Fabian.weykamp@med.uni-heidelberg.de+49-6221-56 8202

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026